● pepmg Research Desk · Peer-reviewed evidence review
What the research says about vilon
A neutral summary of the peer-reviewed literature on Vilon, a synthetic Lys-Glu dipeptide bioregulator studied almost entirely by a single research lineage in animal, in-vitro, and human-cell-culture models, with no controlled human clinical trials. Research use only.
Preclinical only — Animal or in-vitro studies only — no controlled human trials. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Vilon is described in the literature as a synthetic dipeptide, Lys-Glu ("KE"), one of the Khavinson-type short peptide bioregulators, studied almost entirely by a single research lineage in animal, in-vitro, and human-cell-culture models [1][6].
- Most of the human-tissue work is in vitro: in cultured lymphocytes from elderly donors, investigators reported that Vilon decondensed ("reactivated") heterochromatin and activated ribosomal genes [1][2][3].
- Animal work reports effects on lifespan and digestive-enzyme activity in aged rodents and mixed-direction results in tumor models, reduced tumor incidence in some chemically induced models but increased incidence in a transgenic mammary model [6][7][8][9][10].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What vilon is
Vilon is described in the literature as a synthetic dipeptide, L-lysyl-L-glutamic acid (Lys-Glu, sometimes abbreviated KE), one of a family of short peptide bioregulators (also called "cytogens") developed by a St. Petersburg research group and studied largely by that single research lineage [1][7]. In the authors' own framing, the KE dipeptide is characterized as having immunomodulatory, oncostatic, and geroprotective properties [5].
Vilon is not an approved medicine. Material sold by third-party research-chemical vendors is offered for laboratory and research use only and is not a regulated pharmaceutical.
What the research has measured
Preclinical onlyThe interventional evidence for vilon is entirely preclinical, animal, in-vitro, and human-cell-culture. The most-cited human-tissue work is in vitro: in cultured lymphocytes taken from elderly donors (reported as 75 to 88 years old), investigators reported that Vilon induced unrolling ("deheterochromatinization") of total heterochromatin and reactivated ribosomal genes, while not decondensing pericentromeric structural heterochromatin [1][2][3]. These are structural chromatin changes measured in donor cells in culture, not measurements of any clinical outcome in people.
In other human-cell systems, the KE dipeptide was reported to modulate proliferative signaling in the human monocytic THP-1 line and to alter the expression and synthesis of the SIRT1, PARP1, and PARP2 proteins during replicative aging of cultured human mesenchymal stem cells [4][5].
Animal work covers aging and tumor models. Subcutaneous vilon administered to mice was reported to increase physical activity and endurance, prolong lifespan, and reduce spontaneous neoplasms [6]. Oral vilon was reported to change digestive-enzyme activity in the gastrointestinal tract of rats of different ages, with the most pronounced increases in older animals [7]. In chemically induced tumor models, vilon was reported to lower the incidence of induced urinary-bladder tumors (tumors in 56% of treated animals versus 75.5% of controls) [8] and of dimethylhydrazine-induced neoplasia (14.3% of treated animals versus 60% of controls) [9]. In a transgenic HER-2/neu mammary-tumor model, by contrast, vilon was reported to produce significant negative effects, including an increased incidence of mammary cancer and a shorter latent period [10].
What the trials report on safety and adverse events
Preclinical onlyThere are no controlled human trials of administered vilon from which to report human adverse-event rates. The human-tissue data are in-vitro studies on donor cells, and the interventional data are in animals and cell cultures [1][4]. The safety statements that exist come from animal work: a mouse lifespan study reported that long-term vilon administration caused no unfavorable effects on animal development and characterized chronic administration as safe in that model [6].
The animal literature is not uniformly benign, however. In a transgenic HER-2/neu mouse model, vilon was reported to increase mammary-tumor incidence and shorten tumor latency, an unfavorable effect in that specific model [10], even though in chemically induced bladder and colon models vilon reduced tumor incidence [8][9]. This model-dependent, direction-mixed picture is a measured research finding in animals, not a human safety characterization.
Because the human data are in-vitro and the interventional data are preclinical, nothing here should be read as a safety guarantee for people. Material sold by research-chemical vendors is not a regulated medicine. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence for vilon is characterized as preclinical: it consists of animal experiments, in-vitro studies, and cell-culture work on human lymphocytes and other human cells from elderly donors, produced almost entirely by a single research lineage, with no controlled human clinical trials [1][3][6]. "Preclinical" describes the design and scope of the published studies, chromatin decondensation in cultured donor cells, enzyme-activity and lifespan changes in rodents, and mixed-direction tumor-model results, not an endorsement and not an anti-aging benefit demonstrated in people [1][6][10].
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 10
- Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people.
- Anti-aging peptide bioregulators induce reactivation of chromatin.
- EPIGENETIC MODIFICATION UNDER THE INFLUENCE OF PEPTIDE BIOREGULATORS ON THE "OLD" CHROMATIN.
- Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line.
- [KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cells aging.].
- Effect of vilon on biological age and lifespan in mice.
- Effect of the dipeptide vilon on activity of digestive enzyme in rats of various ages.
- Inhibitory effect of peptide vilon on the development of induced rat urinary bladder tumors in rats.
- [The effect of vilon (Lys-Glu) on 1.2-dimethylhydrazine-induced neoplasia].
- Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.